Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

Toshiba implements largest 64-slice CT trial evaluation study

Toshiba America Medical Systems : 07 May, 2007  (New Product)
Toshiba America Medical Systems has enrolled 400 patients in the company's CorE 64 (Coronary Evaluation on 64) study that will take place in seven countries.
The study is the largest trial ever initiated evaluating the use of 64-slice CT technology.

The trial's enrollment completion signifies that the study of all patient participants has finished, resulting in the most statistically reliable data available to date.

Toshiba's CorE 64 trial investigates the use of multi-slice CT as the primary diagnostic tool for detecting cardiovascular diseases and disorders, as compared to cardiac catheterization, a costly, invasive technique.

Data collected to date from CorE 64 indicates CT holds a favourable place as a diagnostic alternative to cardiac catheterization and has the potential to change the delivery of healthcare.

'We expect CorE 64 findings to impact the overall reimbursement guidelines for multi-slice CT, resulting in greater patient access to these exams and to have significant economic benefits for 64-slice CT', explained Toshihiro Rifu, senior fellow, Toshiba Medical Systems.

'Additional benefits from this study are already evidenced by the use of CorE 64's preliminary data in two ancillary studies by Johns Hopkins University presented at American College of Cardiology (ACC) annual meeting'.

The CorE 64 multi-centre study participants include nine sites across seven countries: Johns Hopkins University School of Medicine, in Baltimore, Maryland., led by primary investigators Drs Joao A C Lima and Julie Miller Johns Hopkins Bayview Medical Center in Baltimore, Maryland.

Beth Israel Deaconess Medical Center at Harvard in Boston, Massachusetts, USA Leiden University Medical Center in the Netherlands Humboldt University, Campus Charite Mitte in Germany INCOR Heart Institute of the School of Medicine Hospital, Sao Paulo University in Brazil Iwate Medical University in Japan Mount Elizabeth Hospital in Singapore Toronto General Hospital, University Health Network and Mount Sinai Hospital in Canada According to Toshiba's senior director of CT, Doug Ryan, the CorE 64 clinical trial utilises a different approach when compared to previous studies on the topic.

This is attributed in large part to the study's design, which calls for an international, multi-centre approach, bypassing limitations associated with previous studies that focus on one geographic area or utilise smaller patient populations.

'CorE 64 is the first trial that evaluates all of its 400 study participants who are between 50 and 70 percent stenotic, resulting in statistically significant data', noted Ryan.

'We anticipate CorE 64 will set a precedent for all future CT trials conducted by Toshiba and by other leaders in the medical field'.
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo